Chromatin Bioscience is pleased to announce an ongoing research collaboration with Purespring Therapeutics, a precision nephrology company leading the development of targeted, first-in-class genetic ...

BioMarin Pharmaceutical said on Monday it plans to divest its gene therapy, a product once expected to be a blockbuster treatment for a type of rare bleeding disorder.

To solve this critical challenge, he founded Nephrogen in 2022, a biotech startup that uses AI and advanced screening to ...

Intellia Therapeutics said it is pausing two late-stage CRISPR gene-editing trials after a patient in one study was ...

Intellia Therapeutics will find it challenging to survive now that its CRISPR gene-editing treatment has been tied to severe, ...